血肌酐与非ST段抬高急性冠脉综合征冠脉病变程度及其预后

目的:研究血清肌酐(serum creatinine,SCr)与非ST段抬高急性冠脉综合征(non-ST-elevation acute coronary syndrome,NSTE-ACS)患者冠脉病变程度及其预后的关系。方法:对293例患者进行回顾性分析,依据冠脉造影结果分为NSTE-ACS组和非冠心病组。根据Gensini积分系统,评价NSTE-ACS患者冠脉病变程度,并将患者分为轻度病变组、中度病变组和重度病变组。检测患者SCr水平,应用SPSS16.0分析SCr与NSTE-ACS患者冠脉病变程度及其预后关系。结果:(1)与非冠心病组相比,NSTE-ACS患者SCr较高(P0.05);其中,重度冠脉病变NSTE-ACS患者SCr水平尤高(P0.001)。(2)SCr是NSTE-ACS冠脉病变的危险因子;SCr与NSTE-ACS冠脉病变程度呈正相关(r=0.263,P0.000);SCr与NSTE-ACS主要心血管不良事件(Major Adverse Cardiovascular Events,MACE)呈正相关(r=0.183,P0.01)。结论:SCr是NSTE-ACS患者冠脉病变的独立危险因子,且与NSTE-ACS患者预后相关。SCr对于NSTE-ACS的诊疗有潜在临床价值。

Influence of SerumCreatinine on Severity of Coronary Artery Lesions and its Prognosis in patients with Non-ST-elevation Acute Coronary Syndrome

Objective:To explore the correlation between the severity of coronary artery lesion , its prognosis and serumcreatinine (SCr) in patients with non-ST-elevation acute coronary syndrome(NSTE-ACS).Methods:A total of 293 hospitalized patients undergoing coronary angiography with NSTE-ACS were selected in this retrospective study, including patients with NSTE-ACS and normal coronary arteries. The extent and severity of coronary artery lesions is evaluated by Gensini system. Patients with NSTE-ACS were divided into three groups: high lesion group, mild lesion group and low lesion group. SCr was measured and SPSS was used to analyze relation between the severity of coronary artery lesion, its prognosis and SCr in patients with NSTE-ACS.Results:(1) SCr was higher in patients with NSTE-ACS than that in control group (P<0.05); SCr was higher in high lesion group than that in other groups(P<0.01). (2) SCr is an independent risk factor for coronary artery lesion in patients with NSTE-ACS (P<0.05)and had significant correlation with it (r=0.263, P<0.000). SCr also had significant correlation with Major Adverse Cardiac Event(MACE) in NSTE-ACS(r=0.183, P<0.01).Conclusion:SCr is an independent risk factor for coronary artery lesion and is correlated with prognosis in NSTE-ACS. SCr has potential value for diagnosis and treatment of NSTE-ACS.